- What other names is Bitter Melon known by?
- What is Bitter Melon?
- How does Bitter Melon work?
- Are there safety concerns?
- Are there any interactions with medications?
- Dosing considerations for Bitter Melon.
African Cucumber, Ampalaya, Balsam Pear, Balsam-Apple, Balsambirne, Balsamo, Bitter Apple, Bitter Cucumber, Bitter Gourd, Bittergurke, Carilla Fruit, Carilla Gourd, Cerasee, Chinli-Chih, Cundeamor, Fructus Mormordicae Grosvenori, Karavella, Kathilla, Karela, Kareli, Kerala, Kuguazi, K'u-Kua, Lai Margose, Melón Amargo, Melon Amer, Momordica, Momordica charantia, Momordica murcata, Momordique, Pepino Montero, P'u-T'ao, Sorosi, Sushavi, Vegetable insulin, Wild Cucumber.
Bitter melon is a plant. The fruit and seeds are used to make medicine.
Bitter melon is used for various stomach and intestinal disorders including gastrointestinal (GI) upset, ulcers, colitis, constipation, and intestinal worms. It is also used for diabetes, kidney stones, fever, a skin condition called psoriasis, and liver disease; to start menstruation; and as supportive treatment for people with HIV/AIDS.
Topically, bitter melon is used for deep skin infections (abscesses) and wounds.
Bitter melon is used as a vegetable in India and other Asian countries and as an ingredient in some kinds of curries.
Insufficient Evidence to Rate Effectiveness for...
- Diabetes. Research results so far are conflicting and inconclusive. Some studies show that bitter melon fruit, fruit juice, or extract improves glucose tolerance, reduces blood sugar levels, and lowers HbA1c (a measure of blood sugar control over time) in people with type 2 diabetes. However, these studies have some flaws. Other research has not been positive.
- Stomach and intestinal disorders.
- Kidney stones.
- Liver disease.
- Skin abscesses and wounds.
- Other conditions.
Bitter melon contains a chemical that acts like insulin to help reduce blood sugar levels.
Bitter melon fruit is POSSIBLY SAFE for most people when taken by mouth in the short-term. The safety of long-term use (beyond 3 months) is not known. There also is not enough information about the safety of consuming other parts of the bitter melon or applying bitter melon to the skin.
Special Precautions & Warnings:Pregnancy and breast-feeding: Bitter melon is LIKELY UNSAFE when taken by mouth during pregnancy. Certain chemicals in bitter melon fruit, juice, and seeds can start menstrual bleeding and have caused abortion in animals. Not enough is known about the safety of using bitter melon during breast-feeding. Stay on the safe side and avoid use.
Diabetes: Bitter melon can lower blood sugar levels. If you have diabetes and take medications to lower your blood sugar, adding bitter melon might make your blood sugar drop too low. Monitor your blood sugar carefully.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency: People with G6PD deficiency might develop “favism” after eating bitter melon seeds. Favism is a condition named after the fava bean, which is thought to cause “tired blood” (anemia), headache, fever, stomach pain, and coma in certain people. A chemical found in bitter melon seeds is related to chemicals in fava beans. If you have G6PD deficiency, avoid bitter melon.
Surgery: There is a concern that bitter melon might interfere with blood sugar control during and after surgery. Stop using bitter melon at least 2 weeks before a scheduled surgery.
Medications for diabetes (Antidiabetes drugs)Interaction Rating: Moderate Be cautious with this combination.Talk with your health provider.
Bitter melon can decrease blood sugar levels. Diabetes medications are also used to lower blood sugar. Taking bitter melon along with diabetes medications might cause your blood sugar to be too low. Monitor your blood sugar closely. The dose of your diabetes medication might need to be changed.
Some medications used for diabetes include glimepiride (Amaryl), glyburide (DiaBeta, Glynase PresTab, Micronase), insulin, pioglitazone (Actos), rosiglitazone (Avandia), chlorpropamide (Diabinese), glipizide (Glucotrol), tolbutamide (Orinase), and others.
The appropriate dose of bitter melon depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for bitter melon. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, and Insufficient Evidence to Rate (detailed description of each of the ratings).
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Health Solutions From Our Sponsors
Aguwa, C. N. and Mittal, G. C. Abortifacient effects of the roots of Momordica angustisepala. J Ethnopharmacol. 1983;7(2):169-173. View abstract.
Akhtar, M. S. Trial of Momordica charantia Linn (Karela) powder in patients with maturity-onset diabetes. J Pak.Med Assoc 1982;32(4):106-107. View abstract.
Ansari, N. M., Houlihan, L., Hussain, B., and Pieroni, A. Antioxidant activity of five vegetables traditionally consumed by South-Asian migrants in Bradford, Yorkshire, UK. Phytother Res 2005;19(10):907-911. View abstract.
Baldwa VS, Bhandara CM, Pangaria A, and et al. Clinical trials in patients with diabetes mellitus of an insulin-like compound obtained from plant source. Upsala J Med Sci 1977;82:39-41.
Chan, W. Y., Tam, P. P., and Yeung, H. W. The termination of early pregnancy in the mouse by beta-momorcharin. Contraception 1984;29(1):91-100. View abstract.
Chen, Q., Chan, L. L., and Li, E. T. Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr. 2003;133(4):1088-1093. View abstract.
Das, P., Sinhababu, S. P., and Dam, T. Screening of antihelminthic effects of Indian plant extracts: a preliminary report. J Altern Complement Med 2006;12(3):299-301. View abstract.
Dixit, V. P., Khanna, P., and Bhargava, S. K. Effects of Momordica charantia L. fruit extract on the testicular function of dog. Planta Med 1978;34(3):280-286. View abstract.
Dutta PK, Chakravarty AK, CHowdhury US, and Pakrashi SC. Vicine, a favism-inducing toxin from Momordica charantia Linn. seeds. Indian J Chem 1981;20B(August):669-671.
Hulin et al. Intoxication aigue pour Momordica charantica (Sorrossi). A proposdeux cas. Semaine Hospitaux 1988;64:2847-2848.
Khanna, P., Jain, S. C., Panagariya, A., and Dixit, V. P. Hypoglycemic activity of polypeptide-p from a plant source. J Nat.Prod. 1981;44(6):648-655. View abstract.
Kohno, H., Yasui, Y., Suzuki, R., Hosokawa, M., Miyashita, K., and Tanaka, T. Dietary seed oil rich in conjugated linolenic acid from bitter melon inhibits azoxymethane-induced rat colon carcinogenesis through elevation of colonic PPARgamma expression and alteration of lipid composition. Int J Cancer 7-20-2004;110(6):896-901. View abstract.
Krawinkel, M. B. and Keding, G. B. Bitter gourd (Momordica Charantia): A dietary approach to hyperglycemia. Nutr Rev 2006;64(7 Pt 1):331-337. View abstract.
Lee-Huang, S., Huang, P. L., Sun, Y., Chen, H. C., Kung, H. F., Huang, P. L., and Murphy, W. J. Inhibition of MDA-MB-231 human breast tumor xenografts and HER2 expression by anti-tumor agents GAP31 and MAP30. Anticancer Res 2000;20(2A):653-659. View abstract.
Liu, H. L., Wan, X., Huang, X. F., and Kong, L. Y. Biotransformation of sinapic acid catalyzed by Momordica charantia peroxidase. J Agric Food Chem 2-7-2007;55(3):1003-1008. View abstract.
Marles R and Farnsworth N. Antidiabetic Plants and Their Active Constituents: An update. Phytomedicine 1997;2(2):137-189.
Miura, T., Itoh, C., Iwamoto, N., Kato, M., Kawai, M., Park, S. R., and Suzuki, I. Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J Nutr.Sci.Vitaminol.(Tokyo) 2001;47(5):340-344. View abstract.
Nerurkar, P. V., Lee, Y. K., Linden, E. H., Lim, S., Pearson, L., Frank, J., and Nerurkar, V. R. Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2. Br J Pharmacol 2006;148(8):1156-1164. View abstract.
Nerurkar, P. V., Pearson, L., Efird, J. T., Adeli, K., Theriault, A. G., and Nerurkar, V. R. Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J Nutr 2005;135(4):702-706. View abstract.
Ng, T. B., Wong, C. M., Li, W. W., and Yeung, H. W. Insulin-like molecules in Momordica charantia seeds. J Ethnopharmacol. 1986;15(1):107-117. View abstract.
Ng, T. B., Wong, C. M., Li, W. W., and Yeung, H. W. Isolation and characterization of a galactose binding lectin with insulinomimetic activities. From the seeds of the bitter gourd Momordica charantia (Family Cucurbitaceae). Int J Peptide Protein Res 1986;28(2):163-172. View abstract.
Pongnikorn, S., Fongmoon, D., Kasinrerk, W., and Limtrakul, P. N. Effect of bitter melon (Momordica charantia Linn) on level and function of natural killer cells in cervical cancer patients with radiotherapy. J Med Assoc Thai. 2003;86(1):61-68. View abstract.
Raman A and Lau C. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine 1996;2(4):349-362.
Rathi, S. S., Grover, J. K., and Vats, V. The effect of Momordica charantia and Mucuna pruriens in experimental diabetes and their effect on key metabolic enzymes involved in carbohydrate metabolism. Phytother.Res 2002;16(3):236-243. View abstract.
Rebultan, S. P. Bitter melon therapy: an experimental treatment of HIV infection. AIDS Asia 1995;2(4):6-7. View abstract.
Senanayake, G. V., Maruyama, M., Sakono, M., Fukuda, N., Morishita, T., Yukizaki, C., Kawano, M., and Ohta, H. The effects of bitter melon (Momordica charantia) extracts on serum and liver lipid parameters in hamsters fed cholesterol-free and cholesterol-enriched diets. J Nutr Sci Vitaminol.(Tokyo) 2004;50(4):253-257. View abstract.
Senanayake, G. V., Maruyama, M., Shibuya, K., Sakono, M., Fukuda, N., Morishita, T., Yukizaki, C., Kawano, M., and Ohta, H. The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. J Ethnopharmacol 2004;91(2-3):257-262. View abstract.
Shekelle, P. G., Hardy, M., Morton, S. C., Coulter, I., Venuturupalli, S., Favreau, J., and Hilton, L. K. Are Ayurvedic herbs for diabetes effective? J Fam.Pract. 2005;54(10):876-886. View abstract.
Srivastava Y. Antidiabetic and adaptogenic properties of Momordica charantia extract:An experimental and clinical evaluation. Phytother Res 1993;7:285-289.
Stepka W, Wilson KE, and Madge GE. Antifertility investigation on Momordica. Lloydia 1974;37(4):645.
Takemoto, D. J., Dunford, C., and McMurray, M. M. The cytotoxic and cytostatic effects of the bitter melon (Momordica charantia) on human lymphocytes. Toxicon 1982;20(3):593-599. View abstract.
Takemoto, D. J., Jilka, C., and Kresie, R. Purification and characterization of a cytostatic factor from the bitter melon Momordica charantia. Prep.Biochem 1982;12(4):355-375. View abstract.
Tennekoon, K. H., Jeevathayaparan, S., Angunawala, P., Karunanayake, E. H., and Jayasinghe, K. S. Effect of Momordica charantia on key hepatic enzymes. J Ethnopharmacol. 1994;44(2):93-97. View abstract.
Tuekpe, M. K., Todoriki, H., Sasaki, S., Zheng, K. C., and Ariizumi, M. Potassium excretion in healthy Japanese women was increased by a dietary intervention utilizing home-parcel delivery of Okinawan vegetables. Hypertens.Res 2006;29(6):389-396. View abstract.
Virdi, J., Sivakami, S., Shahani, S., Suthar, A. C., Banavalikar, M. M., and Biyani, M. K. Antihyperglycemic effects of three extracts from Momordica charantia. J Ethnopharmacol. 2003;88(1):107-111. View abstract.
Wang, Y. X., Jacob, J., Wingfield, P. T., Palmer, I., Stahl, S. J., Kaufman, J. D., Huang, P. L., Huang, P. L., Lee-Huang, S., and Torchia, D. A. Anti-HIV and anti-tumor protein MAP30, a 30 kDa single-strand type-I RIP, shares similar secondary structure and beta-sheet topology with the A chain of ricin, a type-II RIP. Protein Sci. 2000;9(1):138-144. View abstract.
Wang, Y. X., Neamati, N., Jacob, J., Palmer, I., Stahl, S. J., Kaufman, J. D., Huang, P. L., Huang, P. L., Winslow, H. E., Pommier, Y., Wingfield, P. T., Lee-Huang, S., Bax, A., and Torchia, D. A. Solution structure of anti-HIV-1 and anti-tumor protein MAP30: structural insights into its multiple functions. Cell 11-12-1999;99(4):433-442. View abstract.
Welihinda, J., Arvidson, G., Gylfe, E., Hellman, B., and Karlsson, E. The insulin-releasing activity of the tropical plant momordica charantia. Acta Biol Med Ger 1982;41(12):1229-1240. View abstract.
Wong, C. M., Yeung, H. W., and Ng, T. B. Screening of Trichosanthes kirilowii, Momordica charantia and Cucurbita maxima (family Cucurbitaceae) for compounds with antilipolytic activity. J Ethnopharmacol. 1985;13(3):313-321. View abstract.
Yasui, Y., Hosokawa, M., Kohno, H., Tanaka, T., and Miyashita, K. Troglitazone and 9cis,11trans,13trans-conjugated linolenic acid: comparison of their antiproliferative and apoptosis-inducing effects on different colon cancer cell lines. Chemotherapy 2006;52(5):220-225. View abstract.
Ahmad N, Hassan MR, Halder H, Bennoor KS. Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients (abstract). Bangladesh Med Res Counc Bull 1999;25:11-3. View abstract.
Ali L, Khan AK, Mamun MI, et al. Studies on hypoglycemic effects of fruit pulp, seed, and whole plant of Momordica charantia on normal and diabetic model rats. Planta Med 1993;59:408-12. View abstract.
Anila L, Vijayalakshmi NR. Beneficial effects of flavonoids from Sesamum indicum, Emblica officinalis and Momordica charantia. Phytother Res 2000;14:592-5. View abstract.
Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet 1979:1:607. View abstract.
Baldwa VS, Bhandari CM, Pangaria A, Goyal RK. Clinical trial in patients with diabetes mellitus of an insulin-like compound obtained from plant sources. Ups J Med Sci 1977;82:39-41. View abstract.
Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003;60:356-9. View abstract.
Bourinbaiar AS, Lee-Huang S. The activity of plant-derived antiretroviral proteins MAP30 and GAP31 against herpes simplex virus in vitro. Biochem Biophys Res Commun 1996;219:923-9. View abstract.
Bourinbaiar AS, Lee-Huang S. Potentiation of anti-HIV activity of anti-inflammatory drugs, dexamethasone and indomethacin, by MAP30, the antiviral agent from bitter melon. Biochem Biophys Res Commun 1995;208:779-85. View abstract.
Cakici I, Hurmoglu C, Tunctan B, et al. Hypoglycaemic effect of Momordica charantia extracts in normoglycaemic or cyproheptadine-induced hyperglycaemic mice. J Ethnopharmacol 1994;44:117-21. View abstract.
Cunnick JE, Sakamoto K, Chapes SK, et al. Induction of tumor cytotoxic immune cells using a protein from the bitter melon (Momordica charantia). Cell Immunol 1990;126:278-89. View abstract.
Dans AM, Villarruz MV, Jimeno CA, et al. The effect of Momordica charantia capsule preparation on glycemic control in type 2 diabetes mellitus needs further studies. J Clin Epidemiol 2007;60:554-9. View abstract.
Day C, Cartwright T, Provost J, Bailey CJ. Hypoglycaemic effect of Momordica charantia extracts. Planta Med 1990;56:426-9. View abstract.
Grover JK, Vats V, Rathi SS, Dawar R. Traditional Indian anti-diabetic plants attenuate progression of renal damage in streptozotocin induced diabetic mice. J Ethnopharmacol 2001;76:233-8. View abstract.
Jilka C, Strifler B, Fortner GW, et al. In vivo antitumor activity of the bitter melon (Momordica charantia). Cancer Res 1983;43:5151-5. View abstract.
Jiratchariyakul W, Wiwat C, Vongsakul M, et al. HIV inhibitor from Thai bitter gourd. Planta Med 2001;67:350-3. View abstract.
Leatherdale B, Panesar RK, Singh G, et al. Improvement in glucose tolerance due to Momordica charantia. Br Med J (Clin Res Ed) 1981;282:1823-4. View abstract.
Lee-Huang S, Huang PL, Chen HC, et al. Anti-HIV and anti-tumor activities of recombinant MAP30 from bitter melon. Gene 1995;161:151-6. View abstract.
Lee-Huang S, Huang PL, Huang PL, et al. Inhibition of the integrase of human immunodeficiency virus (HIV) type 1 by anti-HIV plant proteins MAP30 and GAP31. Proc Natl Acad Sci U S A 1995;92:8818-22. View abstract.
Lee-Huang S, Huang PL, Nara PL, et al. MAP 30: a new inhibitor of HIV-1 infection and replication. FEBS Lett 1990;272:12-8. View abstract.
Leung SO, Yeung HW, Leung KN. The immunosuppressive activities of two abortifacient proteins isolated from the seeds of bitter melon (Momordica charantia). Immunopharmacol 1987;13:159-71. View abstract.
Naseem MZ, Patil SR, Patil SR, et al. Antispermatogenic and androgenic activities of Momordica charantia (Karela) in albino rats. J Ethnopharmacol 1998;61:9-16. View abstract.
Raman A, et al. Anti-diabetic properties and phytochemistry of Momordica charantia L. (Cucurbitaceae). Phytomedicine 1996;294.
Sarkar S, Pranava M, Marita R. Demonstration of the hypoglycemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res 1996;33:1-4. View abstract.
Schreiber CA, Wan L, Sun Y, et al. The antiviral agents, MAP30 and GAP31, are not toxic to human spermatozoa and may be useful in preventing the sexual transmission of human immunodeficiency virus type 1. Fertil Steril 1999;72:686-90. View abstract.
Shibib BA, Khan LA, Rahman R. Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem J 1993;292:267-70. View abstract.
Srivastava Y, Venkatakrishna-Bhatt H, Verma Y, et al. Antidiabetic and adaptogenic properties of Momordica charantia extract: An experimental and clinical evaluation. Phytother Res 1993;7:285-9.
Vikrant V, Grover JK, Tandon N, et al. Treatment with extracts of Momordica charantia and Eugenia jambolana prevents hyperglycemia and hyperinsulinemia in fructose fed rats. J Ethnopharmacol 2001;76:139-43. View abstract.
Welihinda J, et al. Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol 1986;17:277-82. View abstract.